Neutral
●
Proactive Investors
●
about one month ago
Novo Nordisk (NYSE:NVO) (NYSE:NVO), the Danish drugmaker, would be open to considering a direct listing of its shares on the New York Stock Exchange, according to chief executive Mike Doustdar. Doustdar told the Financial Times that he could see advantages to such a move, although he clarified that the Danish pharmaceutical company is not currently exploring a change to its US listing structure.